Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
ISENTRESS tablets, an integrase inhibitor from Merck and Co., Inc., Whitehouse Station, N.J., U.S.A., was as effective as efavirenz at maintaining viral load suppression to undetectable levels and at improving CD4 counts in previously untreated patients through 144 weeks in a Phase II study still underway. Both medicines were administered in combination with two other anti–HIV medicines, tenofovir and lamivudine. These results were presented today at the 5th International AIDS Society's Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa.
Related Articles
Effectiveness of Increasing Emergency Department Patients' Self-perceived Risk for Being Human Immunodeficiency Virus (HIV) Infected Through Audio Computer Self-interview–based Feedback About Reported HIV Risk Behaviors
Academic Emergency Medicine, 11/11/09
Relevance Score: 95%
HIV-Specific Health Care Utilization and Mortality among Tuberculosis/HIV Coinfected Persons
AIDS Patient Care and STDs, 10/06/09
Relevance Score: 95%
Mediators of HIV-related stigma and risk behavior in HIV infected young women
AIDS Care, 11/12/09
Relevance Score: 94%
Sperm May Play Leading Role In Spreading HIV
ScienceDaily, 10/27/09
Relevance Score: 94%
Female sex work and HIV risks in Croatia
AIDS Care, 10/29/09
Relevance Score: 93%
Today in Drug Interactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Drug-Drug Interaction Between Itraconazole and the Protease Inhibitor Lopinavir/Ritonavir
Annals of Pharmacotherapy, 11/25/09
Daptomycin Versus Other Antimicrobial Agents for the Treatment of Skin and Soft Tissue Infections: A Meta-Analysis
Annals of Pharmacotherapy, 11/25/09
Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis
Pharmacogenetics and genomics, 11/23/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease
Lundbeck, 11/30/09
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09
Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
PharmacoEconomics, 11/24/09
Sponsor
Article Search
Sponsor


See Latest Articles


